Mechanisms of acquired resistance to AKT inhibitor capivasertib in AKT1 mutant patient derived breast cancer models

被引：0
|
作者：
Mearns, Sarah
Pearson, Alex
Sim, Li-Xuan
Cutts, Rosalind
Sritharan, Prithika
Shah, Heena
Gulati, Aditi
Williamson, Stuart
Barry, Simon
De-Bruin, Elza
Turner, Nicholas C.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB450
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer
    Bose, Sminu
    Kalinsky, Kevin
    CLINICAL BREAST CANCER, 2021, 21 (03) : E150 - E153
  • [2] Protein quantitation assays for AKT and PTEN to better understand sensitivity and resistance of breast cancer patients to treatment with AKT inhibitor capivasertib
    Ibrahim, Sahar
    Sobsey, Constance A.
    Popp, Robert
    Zahedi, Rene P.
    Batist, Gerald
    Borchers, Christoph H.
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer
    De, Surya K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2025, 25 (06) : 371 - 377
  • [4] Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA
    Han, Z.
    Hong, L.
    Wu, K.
    Han, S.
    Shen, H.
    Liu, C.
    Lan, Y.
    Liu, Z.
    Han, Y.
    Fan, D.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2006, 25 (04) : 601 - 606
  • [5] Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
    Smyth, Lillian M.
    Tamura, Kenji
    Oliveira, Mafalda
    Ciruelos, Eva M.
    Mayer, Ingrid A.
    Sablin, Marie-Paule
    Biganzoli, Laura
    Ambrose, Helen J.
    Ashton, Jack
    Barnicle, Alan
    Cashell, Des D.
    Corcoran, Claire
    de Bruin, Elza C.
    Foxley, Andrew
    Hauser, Joana
    Lindemann, Justin P. O.
    Maudsley, Rhiannon
    McEwen, Robert
    Moschetta, Michele
    Pass, Martin
    Rowlands, Vicky
    Schiavon, Gaia
    Banerji, Udai
    Scaltriti, Maurizio
    Taylor, Barry S.
    Chandarlapaty, Sarat
    Baselga, Jose
    Hyman, David M.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 3947 - 3957
  • [6] Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer
    Ding, Lin
    Jiang, Hui
    Li, Qiangwei
    Li, Qiushuang
    Zhang, Tian-Tian
    Shang, Limeng
    Xie, Bin
    Zhu, Yaling
    Ding, Keshuo
    Shi, Xuanming
    Zhu, Tao
    Zhu, Yong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [7] Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer
    Lin Ding
    Hui Jiang
    Qiangwei Li
    Qiushuang Li
    Tian-Tian Zhang
    Limeng Shang
    Bin Xie
    Yaling Zhu
    Keshuo Ding
    Xuanming Shi
    Tao Zhu
    Yong Zhu
    Journal of Experimental & Clinical Cancer Research, 43
  • [8] Breast cancer - AKT1 wears many hats
    Seton-Rogers, Sarah
    NATURE REVIEWS CANCER, 2007, 7 (06) : 407 - 407
  • [9] Akt1 governs breast cancer progression in vivo
    Ju, Xiaoming
    Katiyar, Sanjay
    Wang, Chenguang
    Liu, Manran
    Jiao, Xuanmao
    Li, Shengwen
    Zhou, Jie
    Turner, Jacob
    Lisanti, Michael P.
    Russell, Robert G.
    Mueller, Susette C.
    Ojeifo, John
    Chen, William S.
    Hay, Nissim
    Pestell, Richard G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (18) : 7438 - 7443
  • [10] AKT1 Transcriptomic Landscape in Breast Cancer Cells
    George, Bijesh
    Gui, Bin
    Raguraman, Rajeswari
    Paul, Aswathy Mary
    Nakshatri, Harikrishna
    Pillai, Madhavan Radhakrishna
    Kumar, Rakesh
    CELLS, 2022, 11 (15)
12345